Abstract
Two cases of atypical chronic myeloid leukaemia (CML) carrying the t(4;22)(q12;q11) translocation involving the breakpoint cluster region (BCR) and platelet-derived growth factor α receptor (PDGFRA) genes have been recently characterized. We report a third case of atypical CML with the same translocation but with a distinct breakpoint fusing BCR exon 1 with PDGFRA exon 13. The patient had a clinical presentation of CML with progressive transformation in B-cell acute lymphoblastic leukaemia. The involvement of PDGFRA led us to treat the patient with the small organic compound imatinib mesylate/STI571 (Glivec) that blocks the ATP binding site of tyrosine kinases such as Abelson, KIT and platelet-derived growth factor receptors. The patient subsequently achieved a rapid clinical and molecular response clearly demonstrating, for the first time, that Glivec is active against PDGFRA in vivo. Therefore, our study expands the list of Glivec targets and has direct biological and also clinical implications.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, Chase A, Chessells JM, Colombat M, Dearden CE, Dimitrijevic S, Mahon FX, Marin D, Nikolova Z, Olavarria E, Silberman S, Schultheis B, Cross NC and Goldman JM . (2002). N. Engl. J. Med., 347, 481–487.
Baxter EJ, Hochhaus A, Bolufer P, Reiter A, Fernandez JM, Senent L, Cervera J, Moscardo F, Sanz MA and Cross NC . (2002). Hum. Mol. Genet., 11, 1391–1397.
Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ and Lydon NB . (2000). J. Pharmacol. Exp. Ther., 295, 139–145.
Cools J, Bilhou-Nabera C, Wlodarska I, Cabrol C, Talmant P, Bernard P, Hagemeijer A and Marynen P . (1999). Blood, 94, 1820–1824.
Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD and Joensuu H . (2002). N. Engl. J. Med., 347, 472–480.
Druker BJ . (2002). Oncogene, 21, 8541–8546.
Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J and Lydon NB . (1996). Nat. Med., 2, 561–566.
Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD and Fletcher JA . (2003). Science, 299, 708–710.
Magnusson MK, Meade KE, Nakamura R, Barrett J and Dunbar CE . (2002). Blood, 100, 1088–1091.
Maki RG, Awan RA, Dixon RH, Jhanwar S and Antonescu CR . (2002). Int. J. Cancer, 100, 623–626.
McWhirter JR, Galasso DL and Wang JY . (1993). Mol. Cell. Biol., 13, 7587–7595.
Petzer AL, Gunsilius E, Hayes M, Stockhammer G, Duba HC, Schneller F, Grunewald K, Poewe W and Gastl G . (2002). Br. J. Haematol., 117, 623–625.
Rubin BP, Schuetze SM, Eary JF, Norwood TH, Mirza S, Conrad EU and Bruckner JD . (2002). J. Clin. Oncol., 20, 3586–3591.
Thijsen S, Schuurhuis G, van Oostveen J and Ossenkoppele G . (1999). Leukemia, 13, 1646–1674.
van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S and Nielsen OS . (2001). Lancet, 358, 1421–1423.
Acknowledgements
Génopôle Santé Toulouse, France and Association pour la Recherche sur le Cancer (ARC) contract no 4233 and ARECA Network ‘Proteomics and Cancer’.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Trempat, P., Villalva, C., Laurent, G. et al. Chronic myeloproliferative disorders with rearrangement of the platelet-derived growth factor α receptor: a new clinical target for STI571/Glivec. Oncogene 22, 5702–5706 (2003). https://doi.org/10.1038/sj.onc.1206543
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206543
Keywords
This article is cited by
-
Detection of BCR/PDGRFα Fusion Using Dual Colour Dual Fusion BCR/ABL1 Probe: An Illustrative Report
Indian Journal of Hematology and Blood Transfusion (2019)
-
Five years since the discovery of FIP1L1–PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias
Leukemia (2008)
-
Myelofibrosis with a novel translocation, t(1;3)(q31;q23), and response to imatinib mesylate
Leukemia (2007)
-
The tyrosine-kinase inhibitor imatinib induces long-term remission in a patient with chronic myelogenous leukemia with translocation t(4;22)
Leukemia (2007)
-
BCR-ABL-negative chronic myeloid leukemia
Current Hematologic Malignancy Reports (2007)